Komaki (13) reported that no severe RP was observed in patients with lung cancer in the amifostine treatment group, compared with 16% of patients not treated with amifostine (P=0

Komaki (13) reported that no severe RP was observed in patients with lung cancer in the amifostine treatment group, compared with 16% of patients not treated with amifostine (P=0.02). In a study by Phillips (25), it was demonstrated that circulating fibrocytes are associated with the pathogenesis of lung fibrosis. Transforming growth factor- (TGF-) is a key cytokine in the fibrotic process; it is derived mainly from inflammatory cells, and also from pneumocytes and fibroblasts to some degree (17). In epithelial cells, upregulated TGF- stimulates the expression of Smad proteins, which induce the activation of other transcription factors. TGF-/Smad signaling plays an important role in promoting pulmonary fibrosis in various ways, including ROS production, activation of myofibroblasts and fibrocytes, and ECM synthesis (31). In a study by Yano (26), the Smad pathway was shown to contribute to radiation-induced lung fibrosis via the production of type I collagen, and not mitogen-activated protein kinase (MAPK). TGF- can act as a powerful stimulator of collagen synthesis through modulating the transition from a human lung fibroblast to a myofibroblast phenotype, which facilitates lung fibrosis (27,28). In addition to TGF-, inflammatory cytokines derived from T helper (Th) cells also contribute to lung fibrosis. Han (29) noted that, in mice, Th2 immune response-associated factors, including IL-13, GATA-binding protein 3 and arginase 1, may be crucial in the fibrotic process. ECM remodeling, which involves collagen-degrading matrix metalloproteinases (MMPs) and tissue-inhibitors of MMPs, also augments the fibrotic process (30). Yang (30) suggested that MMP-2 and MMP-9, which degrade collagen IV in the basement membrane, were overexpressed in mice post-radiation during the inflammatory response, and destroyed the normal structure of the lung tissue. 3.?Clinical manifestations In the acute phase of RILI, typical clinical symptoms including Mouse monoclonal to PRAK dyspnea, ranging from mild to serious, and dry cough, which is observed in ~60% of patients with RP. Low-grade temporal fever is uncommon, and occurs in ~10% of cases. Upon physical examination in cases of suspected RILI, there may be no apparent abnormalities. However, rare signs such as pleural friction rub, moist Nicaraven rales, and consolidation may be heard occasionally in some cases, in addition to the common presentations (1). These manifestations may be complicated by pre-existing lung disease, such as chronic obstructive pulmonary disease (32). The incidence of fatal RP Nicaraven is low; in a study by Palma (33), it appeared in only 1.9% of cases in all patients who accepted concurrent chemoradiation therapy for non-small cell lung cancer (NSCLC). Radiation fibrosis, which develops in the later phase of RILI, is a scarring disease that can markedly reduce the pulmonary function (32). It may be developed without the patient having suffered the acute phase. Different degrees of respiratory difficulty can occur in fibrotic patients. Chronic pulmonary insufficiency commonly evolves in patients with a large volume of irradiated lung tissue, and this facilitates the development of pulmonary hypertension or even cor pulmonale (pulmonary heart disease) (1). As a restrictive disease, pulmonary function test outcomes in RP patients, including the first expiratory volume in Nicaraven 1 sec (measuring gas movement) and the forced vital capacity (indicating lung capacity), are reduced (16). Carbon monoxide diffusion capacity (DLCO), an essential test that evaluates the gas diffusion condition of RILI patients, decreases significantly when the local radiation dose in normal lung tissue totals 13 Gy (34). DLCO loss tends to increase according to radiation dose (~72% in patients who received 10C20 Gy, and ~90% in patients who received 20 Gy) (34). However, the severity of lung injury is usually defined by the presentation of clinical symptoms and the corresponding treatment strategies, not pulmonary function indexes (16,34). 4.?Imaging findings In cases of suspected RILI, non-invasive radiological imaging, including chest radiography, computed tomography (CT), single-photon emission CT (SPECT), magnetic resonance imaging (MRI) and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), may be applied to evaluate the damaged region and potentially predict the corresponding clinical features (6). Various radiological abnormalities associated with RILI may.